Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 10/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742452 | 0.87 | CYP1A2 (0.60) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2587466 | 0.84 | BCHE (1.00) | BCHEMEN1KMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL4456317 | 0.83 | BCHE (0.97) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL5573633 | 0.81 | CHRM2 (0.60) | MEN1KMT2AALDH1A1 | |
| SCHEMBL26096633 | 0.80 | BCHE (0.70) | BCHEMEN1KMT2A | |
| SCHEMBL14197915 | 0.80 | ALDH1A1 (0.54) | BCHEMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL894215 | 0.79 | BCHE (0.85) | BCHEMEN1KMT2A | |
| SCHEMBL6324640 | 0.79 | BCHE (0.70) | BCHEMEN1KMT2AALDH1A1 | |
| SCHEMBL7760590 | 0.79 | BCHE (1.00) | BCHEMEN1KMT2AMAPK1 | |
| SCHEMBL11069984 | 0.79 | BCHE (1.00) | BCHEMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE | 2005-10-13 | — | — | US | disclosed |
| EP-1442018-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037865-A1 | NOVEL ANTICANCER COMPOUNDS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228017-A1 | Novel anticancer compounds | TP53, ABCG2, MCL1 | BCHE 3800/4885MEN1 1347/4885KMT2A 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.